At the time of writing, Mural Oncology plc [MURA] stock is trading at $2.41, up 133.98%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MURA shares have gain 121.10% over the last week, with a monthly amount drifted -40.79%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mural Oncology plc [NASDAQ: MURA] stock has seen the most recent analyst activity on March 25, 2025, when Raymond James downgraded its rating to a Outperform but kept the price target unchanged to $18 for it. Previously, Morgan Stanley downgraded its rating to Equal-Weight on March 25, 2025. On June 28, 2024, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $15 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $13 on April 04, 2024.
For the past year, the stock price of Mural Oncology plc fluctuated between $0.95 and $4.74. Mural Oncology plc [NASDAQ: MURA] shares were valued at $2.41 at the most recent close of the market.
Analyzing the MURA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.76, Equity is -0.68 and Total Capital is -0.97. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.0100 points at the first support level, and at 1.6100 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.0100, and for the 2nd resistance point, it is at 3.6100.
Ratios To Look Out For
It is important to note that Mural Oncology plc [NASDAQ:MURA] has a current ratio of 5.83. As well, the Quick Ratio is 5.83, while the Cash Ratio is 4.41.
Transactions by insiders
Recent insider trading involved Loew Caroline, Officer, that happened on Mar 04 ’25 when 4313.0 shares were purchased. , Keson-Brookes Maiken completed a deal on Mar 05 ’25 to sell 1469.0 shares. Meanwhile, Keson-Brookes Maiken sold 1262.0 shares on Mar 04 ’25.
